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Abstract 
Due to the increase of oral agents nonadherence is an emerging challenge in cancer care. We evaluated how well 
different assessments match and how adherence could be measured in routine care. For this purpose patients suf-
fering from metastatic solid tumors who were treated with oral anticancer drugs in an oncology group practice were 
surveyed. Attending oncologists answered a questionnaire, too, and a retrospective analysis of prescription data was 
conducted. Caregivers who were eligible for an interview were surveyed additionally. 128 patients (70 % female) with 
a median age of 69 years (36–88) took part, 95 % of all approached patients. 56 % suffered from metastatic breast can-
cer, 44 % from other metastatic solid tumors. 65 caregivers (60 % female) with a median age of 62 years (21–82) were 
interviewed as well. Patients were assessed in 84 % as very reliable in medication-taking by their oncologists. This high 
adherence rate was supported by patients, caregivers and prescription data. However, concordance between assess-
ments of patients, caregivers and oncologists was not substantial. Our method of considering different perspectives 
to assess adherence has to be improved and validated but could help to evaluate adherence with oral cancer therapy 
in routine care.
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Background
Drugs do not work in patients who do not take them 
(Foulon et al. 2011). Adherence with oral drugs, defined 
as the extent to which patients take medications as pre-
scribed (Barron et  al. 2007; Osterberg and Blaschke 
2005), is a challenge of increasing interest (Ziller et  al. 
2009). Consequences of nonadherence are far-reach-
ing, both from an economic standpoint and in terms of 
morbidity and mortality (Dezii 2009; Puts et  al. 2014). 
Adherence rates of less than 80  % were associated with 
poorer survival in breast cancer patients taking tamox-
ifen (McCowan et  al. 2008), similar results were found 
in various studies on chronic myeloid leukemia (Ibra-
him et al. 2011; Marin et al. 2010; Al-Barrak and Cheung 
2013). The monetary waste associated with nonadher-
ence is estimated for the US between $100 billion (Dezii 
2009) and $300 billion a year (Foulon et al. 2011; DiMat-
teo 2004). Patients are optimally adherent if no doses are 
missed, no extra doses are taken, and no doses are taken 
in the wrong quantity or at the wrong time (Ruddy et al. 
2009). The terms adherence and compliance can be used 
synonymously (Ruddy et al. 2009); persistence, defined as 
continuing treatment for the prescribed duration (Hoh-
neker et al. 2011), should be distinguished (Ruddy et al. 
2009; Cramer et al. 2008).
Despite a substantial number of studies in the past dec-
ades (DiMatteo 2004; Vermeire et  al. 2001) there is still 
no “gold-standard” method (Foulon et al. 2011; Grymon-
pre et al. 2006; Vermeire et al. 2001; Banning 2008, 2012; 
Waterhouse et  al. 1993; Escalada and Griffiths 2006) in 
measuring adherence and only a combination of meas-
ures can maximize accuracy (Osterberg and Blaschke 
2005; Wang et al. 2004; Zahrina et al. 2014).
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Self-report instruments are cheap, easy to use and 
uncomplicated to score (Foulon et  al. 2011) but fraught 
with difficulties, including recall issues and reluctance to 
admit nonadherence (Palmieri and Barton 2007; Ruddy 
et al. 2009; Wang et al. 2004; Figueiredo Junior and Foro-
nes 2014). For pill counts patients are required to return 
unused pills at each next visit (Foulon et al. 2011), but like 
self-reports they may be inaccurate and open to manipu-
lation (Palmieri and Barton 2007; Ruddy et  al. 2009). 
Rates of prescription refills are objective and easy to 
obtain but a prescription refill is not equivalent to inges-
tion of medication (Osterberg and Blaschke 2005). Drug 
levels in blood or urine or other physiological parameters 
may be more effective, but are subject to individual dif-
ferences because of pharmacokinetic factors (Palmieri 
and Barton 2007) and for most oral anticancer drugs 
the available markers are not fully validated or sensitive 
and reliable enough to assess adherence (Foulon et  al. 
2011). Electronic monitoring may provide the best esti-
mate of patient adherence (Foulon et al. 2011), however 
it is expensive and not always feasible in daily practice 
(Ruddy et al. 2009; Foulon et al. 2011) and an open con-
tainer does not equal tablet ingestion (Palmieri and Bar-
ton 2007). In sum, there are serious problems with each 
method for generating valid and reliable data to give an 
accurate estimate of extent of adherence (Vermeire et al. 
2001).
Due to differences in measurement and research con-
text wide variations in adherence estimates and outcomes 
can be found in the literature (DiMatteo 2004). Accord-
ing to World Health Organization (WHO) adherence to 
long-term treatments for chronic conditions is estimated 
to be only 50 % (World Health Organization http://www.
who.int/chp/knowledge/publications/adherence_report/
en/#). DiMatteo (2004) conducted a meta-analysis with 
569 studies covering a research period of 50  years and 
found a median adherence of 76  % and a range from 5 
to 100  %; studies involving cancer patients had a mean 
adherence of 79 %. Adherence rates of patients using oral 
anticancer agents ranging from 20 to 100  % have been 
reported elsewhere (Ruddy et  al. 2009; Partridge et  al. 
2002, 2003).
In the longer term, oral cancer therapy may well be 
the rule rather than the exception (O’Neill and Twelves 
2002). Given this shift and the often required longer term 
use (Weingart et al. 2008; Barton 2011), adherence is an 
emerging challenge in cancer care (Barton 2011; Owusu 
et al. 2008). In oncology, adherence has been investigated 
most often in breast cancer patients (Barron et al. 2007; 
Ziller et al. 2009; Banning 2012; Waterhouse et al. 1993; 
Owusu et al. 2008) or in patients suffering from chronic 
myeloid leukemia (Ibrahim et  al. 2011; Marin et  al. 
2010; Al-Barrak and Cheung 2013; Eliasson et al. 2011). 
Breast cancer patients have been assessed typically in 
an early stage of disease and there is only little informa-
tion on the adherence with palliative treatments (World 
Health Organization http://www.who.int/chp/knowl-
edge/publications/adherence_report/en/#). Nevertheless 
some studies have been recently published investigating 
adherence with oral chemotherapy or targeted agents in 
patients suffering from metastatic breast cancer (Figue-
iredo Junior and Forones 2014; daCosta DiBonaventura 
et al. 2014), metastatic colorectal cancer (Figueiredo Jun-
ior and Forones 2014), metastatic castration-resistant 
prostate cancer (Smith et al. 2015), metastatic renal cell 
cancer (Wolter et al. 2012), advanced non-small cell lung 
cancer (Timmers et al. 2015) and advanced gastric cancer 
(Yagasaki et al. 2015).
The objectives of the present study were as follows:
1. Assessment of medication-taking
2. Assessment of adherence with oral anticancer drugs
3. Concordance of adherence assessments of patients, 
caregivers and oncologists
To the best of our knowledge this is the first evalua-
tion of adherence in cancer patients with metastatic solid 
tumors who are treated in an oncology group practice.
Methods
All patients who suffered from a metastatic solid tumor 
and received oral anticancer therapy (cytotoxic or hor-
monal) were identified. Eligible patients were informed 
by their oncologist and gave written informed consent. 
The interviews were carried out by study nurses and 
lasted 10–15  min. The standardized computer-assisted 
questionnaire covered the following areas: handling of 
and attitudes to drugs in general, tolerability and efficacy 
of cancer treatment, importance of therapy for the own 
health, self-reported adherence and handling of adher-
ence problems.
For all eligible caregivers additional interviews with 
the main topic patient’s reliability with medication-tak-
ing were conducted. Caregivers had been identified by 
the patients during their interviews with the help of an 
open-ended question as to persons who support them in 
medication-taking.
A written survey of the attending oncologists with the 
topics tolerability and efficacy of the prescribed antican-
cer drug and the reliability of the patient with medica-
tion-taking was performed for all investigated patients.
Tolerability and efficacy of anticancer drugs were eval-
uated by patients and attending oncologists with the help 
of a Likert-scale ranging from 1 to 5. “1” meant that the 
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therapy was “very well tolerated” or “very effective” and 
“5” that the treatment was “not at all” tolerable or effec-
tive. Reliability of patients in medication-taking was 
assessed by the attending oncologist and the caregiver 
using a five-point scale ranging from “1” “very reliable” to 
“5” “not reliable at all”.
In addition, a retrospective analysis of the medi-
cal treatment data was carried out for all patients using 
medical records and checking prescriptions for deviation 
from the documented treatment regimen. Anticancer 
drugs were thought to be prescribed only by oncologists. 
As an assessment period the previous 6  months were 
used.
The above mentioned interviews of patients, caregivers 
and attending doctors were developed according to exist-
ing literature and used in a small number of patients in 
terms of a pre-test; they are not validated so far.
The issue of adherence was thus classified from 3 or 4 
different and independent perspectives per patient:
1. survey of patients
2. survey of attending doctors
3. survey of caregivers (if possible)
4. retrospective analysis of prescription data
Statistical analyses were performed using SPSS 19. Fre-
quencies, medians and means were calculated to describe 
the data. Concordance analyses of caregivers’ and oncol-
ogists’ assessments were conducted using Lin’s Concord-
ance Correlation Coefficient and Cohen’s Kappa. These 
analyses had to be limited to patients whose caregiv-
ers had carried out an interview. Associations between 
patients’ self-reports and assessments of caregivers and 
attending doctors were evaluated with Chi square trend 
tests.
Missing values occurred only sporadically; if so, fewer 
cases were included in the analyses. The entire project 
had an exploratory character, specific hypotheses were 
not verified.
Results
A total of 135 patients were approached, 95  % partici-
pated. Overall 128 patients (70 % female) with a median 
age of 69  years (36–88  years) were interviewed. 56  % 
suffered from metastatic breast cancer, 44 % from other 
metastatic solid tumors.
65 caregivers (60  % female) with a median age of 
62  years (21–82  years) could be questioned as well. 
Caregivers were partners in 69  % and children in 23  % 
and lived in 69 % of cases in the same household as the 
patient. Patients’ and caregivers’ characteristics are 
depicted in Table 1.
Table 1 Patients’ and caregivers’ characteristics
Patients (N = 128)
Sex
 Female n = 89 (70 %)
 Male n = 39 (30 %)
Age at the time of the interview
 Median (range) 69 years (36–88)
Diagnoses
 Metastatic breast cancer n = 72 (56 %)
 Metastatic prostate cancer n = 18 (14 %)
 Metastatic renal cell cancer n = 9 (7 %)
 Other metastatic solid tumors n = 29 (23 %)
Administered oral anticancer drugs
 Hormonal therapies
  Letrozole n = 17 (13 %)
  Abiraterone acetate n = 11 (9 %)
  Exemestan n = 11 (9 %)
  Anastrozole n = 10 (8 %)
  Exemestane/everolimus n = 7 (5 %)
  Other hormonal therapies n = 13 (10 %)
 Oral chemotherapies
  Capecitabine n = 27 (21 %)
  Other chemotherapies n = 7 (5 %)
 Capecitabine + hormonal therapy n = 2 (2 %)
 Signal transduction inhibitors
  Pazopanib n = 7 (5 %)
  Other signal transduction inhibitors n = 15 (12 %)
 Temozolomide + vemurafenib n = 1 (1 %)
Level of education
 No educational qualification n = 2 (2 %)
 Secondary school n = 106 (83 %)
 A levels n = 12 (9 %)
 University n = 8 (6 %)
Employment status
 Employed n = 16 (13 %)
 Retired n = 99 (77 %)
 Not employed n = 13 (10 %)
Caregivers (N = 65)
 Sex
  Female n = 39 (60 %)
  Male n = 26 (40 %)
 Age at the time of the interview
  Median (range) 62 years (21–82)
 Relationship to the patient
  Partner n = 45 (69 %)
  Child n = 15 (23 %)
  Other n = 5 (8 %)
 Living in the same household
  Yes n = 45 (69 %)
  No n = 20 (31 %)
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Assessment of medication‑taking
52  % of patients took their medications straight from 
the packaging. 43  % used a pill dispenser and prepared 
pills most often for a week (22  %) or a day (20  %) in 
advance. 31  % were supported by another person, usu-
ally by reminding (18 %) and/or by preparation in a pill 
dispenser (16  %). Assessments of trained interviewers 
showed that 75 % of patients were able to name their can-
cer medications correctly and completely without any 
help. After presentation of personal prescription sheets 
additional 17 % identified their anticancer drugs properly 
and completely, in 7  % the responses remained incom-
plete and/or incorrect. According to treatment files, 
patients took 7 (1–19) different medications in median, 
the median number of oral anticancer drugs was 1 (1–4).
Tolerability of anticancer drugs was rated quite simi-
larly by patients (1.8) and physicians (1.7). Men (1.7) 
and patients receiving hormonal therapy (1.6) indicated 
a slightly better tolerance than women (1.9) and patients 
receiving oral chemotherapy (1.9). 35 patients could not 
answer the question of therapeutic effectiveness. The 
remaining 93 patients assessed treatment efficacy as high 
(1.6). Men (1.3) and patients receiving hormonal therapy 
(1.4) perceived a better therapeutic efficacy than the cor-
responding control groups (1.7 and 1.9).
Assessment of adherence with oral anticancer drugs
Deviation between number of prescribed pills and the, 
according to the treatment regimen, necessary number 
was less than 10 % in 85 % of patients, between 10 and 
20 % in 8 % and more than 20 % in 6 % of patients. In 19 
patients prescription rates could not be calculated exactly 
due to lacking data. 88  % of respondents indicated to 
take the prescribed medication always or almost always 
exactly as prescribed.
Patient’s reliability in medication-taking was assessed 
both from the attending oncologist and from the car-
egiver using a five-point scale. Oncologists estimated 
the patients in 84 % of cases as very reliable, with a mean 
of 1.3 for all patients. In further analyses no differences 
between age groups, cancer diagnoses, type of prescribed 
medication and sex could be found. Patients living alone 
(1.6) were assessed less adherent than patients who lived 
together with another person (1.2). Mean values of sub-
groups can be depicted in Table 2.
Assessments of adherence from different perspectives 
and analyses of treatment files are summarized in Table 3.
Concordance of adherence assessments of patients, 
caregivers and oncologists
Lin’s concordance correlation coefficient failed to show 
a concordance in assessments of attending doctors and 
caregivers; the computed coefficient of .3248 has to be 
regarded as poor. Inter rater agreement according to 
Cohen’s Kappa was .144 which cannot be regarded as 
substantial, too. Sensitivity was 86 %, specificity 50 %.
Chi square trend tests showed no significant associa-
tions between patients’ self-reports and assessments of 
attending doctors (p = .081) and caregivers (p > .999).
Discussion
Medication‑taking behavior and adherence in general
Nonadherence to oral medication is associated with 
numerous behavioral, psychosocial and other risk 
factors (Zeber et  al. 2013), it may be intentional or 
Table 2 Reliability in  medication-taking—assessed 
from the attending oncologist (mean values)
Total (N = 128) 1.3
5 point scale ranging from “1” “very reliable” to “5” “not reliable at all”
Patients’ characteristics
 Sex
  Female (n = 89) 1.3
  Male (n = 39) 1.2
 Age groups
  65 years and younger (n = 54) 1.3
  66 years and older (n = 74) 1.2
 Diagnoses
  Metastatic breast cancer (n = 72) 1.2
  Other metastatic solid tumors (n = 56) 1.3
 Type of prescribed medication
  Hormonal therapy (n = 69) 1.3
  Oral chemotherapy (n = 34) 1.3
  Signal transduction inhibitors (n = 22) 1.2
 Living in the household
  Living alone (n = 23) 1.6
  Living together with another person (n = 97) 1.2
Table 3 Adherence in  medication-taking—assessed from   
different perspectives
Assessment of patient
 Taking medication always or almost always as pre-
scribed
n = 113 (88 %)
Deviation in prescription data (n = 109)
 Less than 10 % n = 93 (85 %)
 10–20 % n = 9 (8 %)
 More than 20 % n = 7 (6 %)
5 point scale ranging from “1” “very reliable” to “5” “not reliable at all”:
Assessment of oncologists (n = 63)
 Mean value 1.1
Assessment of caregivers (n = 63)
 Mean value 1.2
Page 5 of 7Feiten et al. SpringerPlus  (2016) 5:270 
non-intentional (Vermeire et  al. 2001; Banning 2008; 
Eliasson et  al. 2011). In our population patients with a 
median age of 69  years had to take seven different oral 
drugs in median and only 31 % of these patients received 
support by a caregiver. One can easily imagine that sin-
gle doses could be missed or that overdosing could be an 
issue. But a current review concluded that demographic 
variables, especially age (Ruddy et  al. 2009) and disease 
factors are poor indicators of adherence (Vermeire et al. 
2001). No relationship between adherence and the use of 
a reminder method could be found in a prospective study 
(Timmers et  al. 2015). Nonetheless, our results seem 
to support the finding that patients living alone are less 
adherent (Timmers et al. 2014).
Estimation of adherence with oral anticancer drugs
Cancer patients are often thought to be highly motivated 
by the gravity of their disease, with “too much to lose” 
by being nonadherent (Ziller et  al. 2009; Waterhouse 
et al. 1993; Zahrina et al. 2014; Winterhalder et al. 2011). 
Recent studies reported adherence rates between 82.6 
and 96.8 % in patients suffering from metastatic disease 
(Figueiredo Junior and Forones 2014; Smith et  al. 2015; 
Timmers et al. 2015).
Our self-report data show an adherence-level of 88  % 
of patients indicating to take their prescribed anticancer 
medication always or almost always exactly as prescribed. 
Oncologists assessed the patients in 84 % as very reliable, 
with a mean of 1.3 on the five-point scale. The deviation 
between number of prescribed and necessary number 
of pills was more than 20  % in only 6  % of patients. In 
sum, our results support the conclusion that adherence 
with oral anticancer therapy seems to be higher than 
for medical treatment in general (Zahrina et  al. 2014). 
There are reasons to believe that this comparable high 
level of adherence contributes to favorable outcomes, e.g. 
in patients with metastatic breast cancer (Weide et  al. 
2014).
However, most studies have shown a number of 
patients who may need specific interventions to ensure 
adherence, too (Figueiredo Junior and Forones 2014). 
Based on different and independent data sources in our 
population a small group of about 5–10 % of patients can 
be found who are at risk for nonadherence. For instance 
6  % of patients had a discrepancy between number of 
prescribed and number of necessary pills of more than 
20 %.
Measuring adherence with the help of different 
perspectives: lacking concordance
Several methods can be used to detect nonadherence 
and for each advantages and limitations can be defined 
(Foulon et al. 2011). The simplest method for physicians 
to monitor adherence may be self-report (Ruddy et  al. 
2009) and self-reports are often the only means available 
in routine care even though their accuracy and agreement 
with other data sources remains questionable (Wang et al. 
2004). But an additional perspective of caregivers seems 
to be little helpful, especially with regard to identifica-
tion of patients who are less reliable, since we found a 
specificity of only 50 %. Furthermore we experienced dif-
ficulties in using routine care data to assess adherence in 
medication-taking reliably. Prescription data remained 
unclear for various reasons. Major problems were addi-
tional prescriptions, i.e. aromatase inhibitors or tamoxifen 
by gynecologists, and undocumented changes in regimen.
Nevertheless it is necessary for clinicians to detect 
patients with low adherence as early as possible (Simons 
et al. 2011). We therefore suggest to screen for nonadher-
ent patients with the help of self-report questionnaires 
and to evaluate nonadherence in more detail for patients 
who may be at risk. In this sense our approach could be 
feasible, questionnaires were short and easy to adminis-
ter and notwithstanding a lacking “gold-standard” meas-
ure we believe that it is possible to assess adherence 
conveniently. Furthermore, given the Hawthorne effect, 
a systematic monitoring of patient pill-taking may be as 
well an effective way to improve adherence and persis-
tence (Ruddy et al. 2009).
Methodological considerations
Overall there is only little information on the adher-
ence with palliative treatments of cancer patients 
(World Health Organization 2003 http://www.who.int/
chp/knowledge/publications/adherence_report/en/#), 
since they may have a different motivation to take their 
medication than those receiving an adjuvant therapy 
(McCowan et  al. 2008). The strength of our project is 
the population of unselected real-life patients who suf-
fer from metastatic solid tumors. To our knowledge this 
is the first assessment of adherence in patients who are 
treated in an oncology group practice. According to cur-
rent data approximately 600,000 cancer patients are 
treated annually in specialists’ practices in Germany 
(Berufsverband der Niedergelassenen Hämatologen und 
Onkologen in Deutschland e.V 2012 http://www.bnho.
de/startseite.html).
We believe that in this setting it is feasible to assess 
adherence, only a small expenditure of additional time is 
necessary. But there are serious limitations which have to 
be considered. First of all, a retrospective analysis of pre-
scription data is difficult and there are too many cases in 
which adherence could not be assessed adequately due to 
missing data. Secondly, we could only manage to survey 
about 50 % of all caregivers; analyses of concordance thus 
were limited to only a half of all investigated patients. 
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Further limitations are the sample size of 128 patients 
and the cross-sectional unicenter design which made it 
impossible to address the question of persistence.
Conclusions
Patients suffering from metastatic solid tumors who are 
treated in an oncology group practice seem to be highly 
adherent with oral antineoplastic therapies. Neverthe-
less, a small group of about 5–10 % of patients exists who 
are not fully adherent.
There is no substantial concordance in adherence 
assessments of patients, attending physicians and car-
egivers. Retrospective analyses of prescription data are 
difficult due to lacking data. Still our method of consid-
ering different perspectives to assess adherence seems to 
be suitable in routine care but it has to be improved and 
validated in larger and more reliable trials.
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